Disfunción renal en el paciente cirrótico
DOI:
https://doi.org/10.52784/27112330.136Palabras clave:
función renal, lesión renal aguda, cirrosis hepática, síndrome hepatorrenal.Resumen
La disfunción renal es una complicación común en pacientes con cirrosis avanzada y está asociada a un incremento significativo en la mortalidad. Este deterioro de la función renal puede ser reversible en algunos casos, si se identifica y se trata su etiología. La lesión renal aguda (LRA) de origen prerrenal y la necrosis tubular aguda (NTA) son las entidades más frecuentes en pacientes con enfermedad hepática crónica y cirrosis, constituyendo un desafío en los escenarios clínicos actuales. La aparición de nuevos biomarcadores como la lipocalina asociada a la gelatinasa de neutrófilos (NGAL), puede ser un factor determinante para esclarecer el origen de estas dos entidades. En la actualidad, la clasificación de la enfermedad renal establece que un aumento en la creatinina sérica basal >0,3 mg/dL dentro de las primeras 48 horas, o un incremento mayor al 50% desde la línea de base, son suficientes para definir lesión renal aguda, por lo cual, cambios leves en la creatinina sérica en un periodo corto de tiempo, contribuyen a una identificación temprana y previenen desenlaces negativos. Esta revisión de tema abordará la lesión renal aguda en cirrosis desde la fisiopatología, la clasificación actual según guías internacionales, los avances en biomarcadores y las principales etiologías, finalizando con un abordaje general y estrategias de prevención.
Descargas
Referencias bibliográficas
Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008;48:2064-2077. https://doi.org/10.1002/hep.22605.
Wu CC, Yeung LK, Tsai WS, Tseng CF, Chu P, Huang TY, et al. Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. Clin Nephrol 2006;65:28-33. https://doi.org/10.5414/cnp65028.
Montoliu S, Ballesté B, Planas R, Alvarez MA, Rivera M, Miquel M, et al. Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites. Clin Gastroenterol Hepatol 2010;8:616-622; quiz e680. https://doi.org/10.1016/j.cgh.2010.03.029.
Weismüller TJ, Prokein J, Becker T, Barg-Hock H, Klempnauer J, Manns MP, et al. Prediction of survival after liver transplantation by pre-transplant parameters. Scand J Gastroenterol 2008;43:736-746. https://doi.org/10.1080/00365520801932944.
Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-1157. https://doi.org/10.1002/hep.1840080532.
Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014;383:1749-1761. https://doi.org/10.1016/s0140-6736(14)60121-5.
Bauer TM, Schwacha H, Steinbrückner B, Brinkmann FE, Ditzen AK, Aponte JJ, et al. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol 2002;97:2364-2370. https://doi.org/10.1111/j.1572-0241.2002.05791.x.
Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 2014;513:59-64. https://doi.org/10.1038/nature13568.
Clària J, Stauber RE, Coenraad MJ, Moreau R, Jalan R, Pavesi M, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. Hepatology 2016;64:1249-1264. https://doi.org/10.1002/hep.28740.
Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Primers 2018;4:23. https://doi.org/10.1038/s41572-018-0022-7.
Fernández J, Fernández-Balsells M, Acevedo J, Arroyo V. Insuficiencia suprarrenal relativa en la insuficiencia hepática aguda y crónica. Gastroenterol Hepatol 2008;31:606-611. https://doi.org/10.1157/13128301.
Acevedo J, Fernández J, Prado V, Silva A, Castro M, Pavesi M, et al. Relative adrenal insufficiency in decompensated cirrhosis: Relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death. Hepatology 2013;58:1757-1765. https://doi.org/10.1002/hep.26535.
Risør LM, Bendtsen F, Møller S. Immunologic, hemodynamic, and adrenal incompetence in cirrhosis: impact on renal dysfunction. Hepatol Int 2015;9:17-27. https://doi.org/10.1007/s12072-014-9581-1.
Nazar A, Guevara M, Sitges M, Terra C, Solà E, Guigou C, et al. LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. J Hepatol 2013;58:51-57. https://doi.org/10.1016/j.jhep.2012.08.027.
Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut 2015;64:531-537. https://doi.org/10.1136/gutjnl-2014-308874.
Caregaro L, Menon F, Angeli P, Amodio P, Merkel C, Bortoluzzi A, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994;154:201-205.
Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis 2003;41:269-278. https://doi.org/10.1053/ajkd.2003.50035.
Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996;23:164-176. https://doi.org/10.1002/hep.510230122.
Angeli P, Sanyal A, Moller S, Alessandria C, Gadano A, Kim R, et al. Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. Liver Int 2013;33:16-23. https://doi.org/10.1111/j.1478-3231.2012.02807.x.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-212. https://doi.org/10.1186/cc2872.
Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31. https://doi.org/10.1186/cc5713.
Tu KH, Jenq CC, Tsai MH, Hsu HH, Chang MY, Tian YC, et al. Outcome scoring systems for short-term prognosis in critically ill cirrhotic patients. Shock 2011;36:445-450. https://doi.org/10.1097/SHK.0b013e31822fb7e2.
Fagundes C, Guevara M, García-López E, Pereira GH, Solà E, Rodríguez E, et al. Acute Kidney Injury Network (AKIN) criteria for acute renal failure predicts outcome in hospitalized cirrhotic patients. J Hepatol 2011;54:S535-546. https://doi.org/10.1016/S0168-8278(11)61367-6.
Fagundes C, Guevara M, García-lópez E, Pereira GH, Solà E, Martín-Llahí M, et al. Comparison of Akin criteria and conventional criteria for definition of renal impairment in cirrhosis: preliminary results of a prospective study. J Hepatol 2010;52:S319-457. https://doi.org/10.1016/S0168-8278(10)60845-8.
Angeli P, Bernardi M, Villanueva C, Francoz C, Mookerjee RP, Trebicka J, et al. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69:406-460. https://doi.org/10.1016/j.jhep.2018.03.024.
Francoz C, Nadim MK, Durand F. Kidney biomarkers in cirrhosis. J Hepatol 2016;65:809-824. https://doi.org/10.1016/j.jhep.2016.05.025.
Qasem AA, Farag SE, Hamed E, Emara M, Bihery A, Pasha H. Urinary biomarkers of acute kidney injury in patients with liver cirrhosis. ISRN Nephrol 2014;2014:376795. https://doi.org/10.1155/2014/376795.
Ariza X, Solà E, Elia C, Barreto R, Moreira R, Morales-Ruiz M, et al. Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis. PLoS One 2015;10:e0128145. https://doi.org/10.1371/journal.pone.0128145.
Fagundes C, Pépin MN, Guevara M, Barreto R, Casals G, Solà E, et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol 2012;57:267-273. https://doi.org/10.1016/j.jhep.2012.03.015.
Verna EC, Brown RS, Farrand E, Pichardo EM, Forster CS, Sola-Del Valle DA, et al. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci 2012;57:2362-2370. https://doi.org/10.1007/s10620-012-2180-x.
Puthumana J, Ariza X, Belcher JM, Graupera I, Ginès P, Parikh CR. Urine interleukin 18 and lipocalin 2 are biomarkers of acute tubular necrosis in patients with cirrhosis: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2017;15:1003-1013. https://doi.org/10.1016/j.cgh.2016.11.035.
Belcher JM, Sanyal AJ, Peixoto AJ, Perazella MA, Lim J, Thiessen-Philbrook H, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 2014;60:622-632. https://doi.org/10.1002/hep.26980.
Bihorac A, Chawla LS, Shaw AD, Al-Khafaji A, Davison DL, Demuth GE, et al. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am J Respir Crit Care Med 2014;189:932-939. https://doi.org/10.1164/rccm.201401-0077OC.
Zhang CC, Hoffelt DAA, Merle U. Urinary cell cycle arrest biomarker [TIMP-2]·[IGFBP7] in patients with hepatorenal syndrome. Biomarkers 2019;24:692-699. https://doi.org/10.1080/1354750X.2019.1652347.
Allegretti AS, Ortiz G, Wenger J, Deferio JJ, Wibecan J, Kalim S, et al. Prognosis of acute kidney injury and hepatorenal syndrome in patients with cirrhosis: A prospective cohort study. Int J Nephrol 2015;2015:108139. https://doi.org/10.1155/2015/108139.
Gomes CG de O, de Andrade MVM, Resende Guedes L, Carvalho Rocha H, Gardone Guimarães R, Castro Carvalho FA, et al. Clinical aspects and prognosis evaluation of cirrhotic patients hospitalized with acute kidney injury. Can J Gastroenterol Hepatol 2019;2019:6567850.https://doi.org/10.1155/2019/6567850.
Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-236. https://doi.org/10.1016/0016-5085(93)90031-7.
Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol 2008;48:S93-103. https://doi.org/10.1016/j.jhep.2008.01.010.
Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jiménez W, Arroyo V, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005;41:1282-1289. https://doi.org/10.1002/hep.20687.
Durand F, Graupera I, Ginès P, Olson JC, Nadim MK. Pathogenesis of hepatorenal syndrome: Implications for therapy. Am J Kidney Dis 2016;67:318-328. https://doi.org/10.1053/j.ajkd.2015.09.013.
Barreto R, Fagundes C, Guevara M, Solà E, Pereira G, Rodríguez E, et al. Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. Hepatology 2014;59:1505-1513. https://doi.org/10.1002/hep.26687.
Zipser RD, Radvan GH, Kronborg IJ, Duke R, Little TE. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology 1983;84:697-703.
Ginès P, Titó L, Arroyo V, Planas R, Panés J, Viver J, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988;94:1493-1502. https://doi.org/10.1016/0016-5085(88)90691-9.
Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012;55:1172-1181. https://doi.org/10.1002/hep.24786.
Huggins JT, Doelken P, Walters C, Rockey DC. Point-of-care echocardiography improves assessment of volume status in cirrhosis and hepatorenal syndrome. Am J Med Sci 2016;351:550-553. https://doi.org/10.1016/j.amjms.2016.02.040.
Newell GC. Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis. Am J Kidney Dis 1987;9:183-190. https://doi.org/10.1016/s0272-6386(87)80053-7.
Chawla LS, Dommu A, Berger A, Shih S, Patel SS. Urinary sediment cast scoring index for acute kidney injury: a pilot study. Nephron Clin Pract 2008;110:c145-150. https://doi.org/10.1159/000166605.
Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney International Supplements. 2012; 2:1-138. https://doi.org/10.1038/kisup.2012.1.
Mejía-Vilet JM, Márquez-Martínez MA, Cordova-Sanchez BM, Chapa Ibargüengoitia M, Correa-Rotter R, Morales-Buenrostro LE. A simple risk score for prediction of hemorrhagic complications after a percutaneous renal biopsy. Nephrology (Carlton) 2017;23:523-529. https://doi.org/10.1111/nep.13055.
Tøndel C, Vikse BE, Bostad L, Svarstad E. Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. Clin J Am Soc Nephrol 2012;7:1591-1597. https://doi.org/10.2215/CJN.02150212.
Corapi KM, Chen JLT, Balk EM, Gordon CE. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis 2012;60:62-73. https://doi.org/10.1053/j.ajkd.2012.02.330 .
Korbet SM, Volpini KC, Whittier WL. Percutaneous renal biopsy of native kidneys: a single-center experience of 1,055 biopsies. Am J Nephrol 2014;39:153-162. https://doi.org/10.1159/000358334.
Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology 2015;62:567-574. https://doi.org/10.1002/hep.27709.
Cavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. Hepatology 2016;63:983-992. https://doi.org/10.1002/hep.28396.
Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002;36:941-948. https://doi.org/10.1053/jhep.2002.35819.
Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 2013;58:1836-1846. https://doi.org/10.1002/hep.26338.
Arora V, Maiwall R, Rajan V, Jindal A, Muralikrishna Shasthry S, Kumar G, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology 2020;71:600-610. https://doi.org/10.1002/hep.30208.
Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007;56:1310-1318. https://doi.org/10.1136/gut.2006.107789.
Sridharan K, Sivaramakrishnan G. Vasoactive agents for hepatorenal syndrome: A mixed treatment comparison network meta-analysis and trial sequential analysis of randomized clinical trials. J Gen Intern Med 2018;33:97-102. https://doi.org/10.1007/s11606-017-4178-8.
Thorat A, Jeng LB. Management of renal dysfunction in patients with liver cirrhosis: role of pretransplantation hemodialysis and outcomes after liver transplantation. Semin Vasc Surg 2016;29:227-235. https://doi.org/10.1053/j.semvascsurg.2017.04.001.
Zhang Z, Maddukuri G, Jaipaul N, Cai CX. Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin. J Crit Care 2015;30:969-974. https://doi.org/10.1016/j.jcrc.2015.05.006.
Tolwani A. Continuous renal-replacement therapy for acute kidney injury. N Engl J Med 2012;367:2505-2514. http://dx.doi.org/10.1056/NEJMct1206045.
Francoz C, Durand F, Kahn JA, Genyk YS, Nadim MK. Hepatorenal Syndrome. Clin J Am Soc Nephrol 2019;14:774-781. https://doi.org/10.2215/cjn.12451018.
Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl 2011;17:1328-1332. https://doi.org/10.1002/lt.22395.
Terg R, Fassio E, Guevara M, Cartier M, Longo C, Lucero R, et al. Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study. J Hepatol 2008;48:774-779. https://doi.org/10.1016/j.jhep.2008.01.024.
Brinch K, Møller S, Bendtsen F, Becker U, Henriksen JH. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J Hepatol 2003;39:24-31. https://doi.org/10.1016/s0168-8278(03)00160-0.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
La política de reconocimiento de autoría de Hepatología se basa en los criterios indicados por el ICMJE para conferir crédito de un trabajo a una persona, a la vez que se le atribuye responsabilidad por la publicación del mismo.
